Evolution Surgical, Inc
$74.8K 667 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Aspira Women's Health Inc
Aspira Women's Health Inc reported $74,735.86 across General Payments, Research, and Ownership to 3,127 physicians and teaching hospitals across 3,127 transactions.
- $74.7K Below-median payer
- All-tracks total
- 3,127 Top quartile volume
- Transactions
- 3,127 Top quartile reach
- Recipients
- −$3.2K
- General Payments vs PY2023
Aspira Women's Health Inc reported $74,735.86 across all CMS Open Payments tracks (General + Research + Ownership) to 3,127 physicians and teaching hospitals in Program Year 2024 - ranking #1257 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $74,735.86, averaging $23.90 per recipient.
Aspira Women's Health Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
22/100
Total payments
F
11/100
Transaction volume
F
33/100
Physician reach
F
34/100
Payment type diversity
F
10/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer aspira-women-s-health-inc Aspira Women's Health Inc
$74.7K · #1257/1,925 · 0.0% industry · PY2024
- TOT $74.7K
- RANK #1257
- SHARE 0.0%
- TXN 3,127
- RCP 3,127
- CAT 1
- GEN $74.7K
- ΔGEN −$3.2K
- TOP1 0.6%
- PY 2024
Volume peers
Nearest volume peer: Evolution Surgical, Inc ($74.8K)
Aspira Women's Health Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Aspira Women's Health Inc's CMS-reported General Payments decreased by $3.2K (−4.1%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: ASPIRA WOMEN'S HEALTH INCPY2023: ASPIRA WOMEN'S HEALTH INCPY2024: Aspira Women's Health Inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $77,901.96
- PY2024
- $74,735.86
What the Data Shows for Aspira Women's Health Inc
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Aspira Women's Health Inc that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
Of the 1 general-payment categories charted below, "Food and Beverage" is the largest at $74.7K across 3,127 transactions, 100.0% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 1 types of general payments, Aspira Women's Health Inc's largest category was "Food and Beverage" at $74.7K - 100.0% of General Payments.
How Aspira Women's Health Inc divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $74.7K | 3,127 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $2,117.84 (2.8%) of $74,735.86 in this company's General Payments records across 2,243 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Aspira Women's Health Inc
The five named recipients with the highest reported General Payments from this company
- 1
Devin Trevor
$463.52 across 11 reported transactions
- 2
Karen Lyons
$429.92 across 10 reported transactions
- 3
Courtney Maxfield
$413.52 across 9 reported transactions
- 4
Helen Cavasin
$411.56 across 12 reported transactions
- 5
Shebna Unes Kunju
$399.32 across 10 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Aspira Women's Health Inc ranks #1257 of 1,925 by total payments (bottom 35% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,828 of 1,838 by HHI (bottom 1% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Aytu BioPharma, Inc. : $14.7K total payments, HHI 17
- Lilly USA, LLC : $46.6M total payments, HHI 16
- 180 Medical, Inc. : $86.9K total payments, HHI 13
- Janssen Biotech, Inc. : $30.9M total payments, HHI 13
- Amphastar Pharmaceuticals, Inc. : $41.3K total payments, HHI 13
- E.R. Squibb & Sons, L.L.C. : $31.0M total payments, HHI 12
- Aspira Women's Health Inc (this company) : $74.7K total payments, HHI 12
- Corium, LLC : $1.7M total payments, HHI 11
- Novo Nordisk Inc : $25.5M total payments, HHI 9
- Beta Bionics, Inc. : $243.6K total payments, HHI 8
- Innovation Technologies Inc : $205.0K total payments, HHI 8
- Shield Therapeutics Inc : $548.7K total payments, HHI 7
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Aspira Women's Health Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Aspira Women's Health Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Aspira Women's Health Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Ascend Therapeutics US, LLC
$74.6K 282 recipients
Compare payment profiles
Lightbody Medical Technologies Inc
$74.3K 678 recipients
Compare payment profiles
Pinnacle Biologics, Inc
$75.4K 342 recipients
Compare payment profiles
Medexus Pharma, Inc.
$75.6K 57 recipients
Compare payment profiles
Clariance SAS
$73.8K 57 recipients
Compare payment profiles
Put this to use
Aspira Women's Health Inc ranks #1257 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Aspira Women's Health Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.